Aurinia Pharmaceuticals(NASDAQ) AUPH

Aurinia Pharmaceuticals Inc. helps adults manage a serious kidney disease. Their main medicine treats patients with active lupus nephritis. The company develops new treatments for other autoimmune conditions.

Medicines for Autoimmune Care

• LUPKYNIS: FDA-approved oral treatment for adults with active lupus nephritis, a serious kidney inflammation; generated $79.4 million in net product sales for the three months ended June 30, 2026.
• Aritinercept: Experimental therapy designed to block two proteins, B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which contribute to autoimmune diseases.
• Licensing and Collaboration: Strategic agreement with Otsuka Pharmaceutical Co., Ltd. for the commercialization of oral voclosporin in Europe, Japan, and other international territories.

Building a Clinical Pipeline

• Introduced LUPKYNIS in January 2021 as the first FDA-approved oral therapy for patients with active lupus nephritis.
• Initiated the PRESERVE study to investigate combining LUPKYNIS with other biologic medications to improve patient outcomes.
• Started clinical development of aritinercept for four different potential medical indications.
• Entered a manufacturing agreement for a dedicated facility in Switzerland, known as the Monoplant, to ensure supply security.
• Repurchased 5.0 million common shares for $74.9 million during the first six months of 2026.

Focus on Specialty Care

Aurinia operates a specialized manufacturing facility in Switzerland to provide supply security for its lead product. Strategic partnerships in Europe and Japan allow the company to reach patients on a global scale.

Momentum in Net Product Sales

• Net product sales reached $153.0 million for the six months ended June 30, 2026, up 21% year over year.
• Gross margin hit 92% for the three months ended June 30, 2026, up from 90% in the prior year period.
• Cash and investments totaled $443.1 million as of June 30, 2026, compared to $398.0 million at the end of 2025.
• Net income rose to $37.4 million for the three-month period ended June 30, 2026.
• Market capitalization grew to $2.2 billion in the second quarter of 2026, up 89.3% year over year.

Evolving Into a Commercial Leader

Aurinia has transitioned from a research firm to a commercial-stage company with a growing revenue base. Its focus on specialized autoimmune treatments and strategic manufacturing partnerships supports its current operational stability.